{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:12:54Z","timestamp":1792807974311,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s13300-021-01050-w","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T11:09:46Z","timestamp":1619694586000},"page":"1613-1630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes"],"prefix":"10.1007","volume":"12","author":[{"given":"Neil S.","family":"Skolnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa J.","family":"Style","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"1050_CR1","unstructured":"United States Renal Data System. 2018 USRDS annual data report. Executive summary. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 2018. https:\/\/www.usrds.org\/annual-data-report\/previous-adrs\/. Accessed 18 Jan 2021."},{"key":"1050_CR2","unstructured":"United States Renal Data System. 2019 USRDS annual data report. Executive summary. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 2019. https:\/\/www.usrds.org\/annual-data-report\/previous-adrs\/. Accessed 18th January 2021"},{"issue":"6","key":"1050_CR3","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1053\/j.ajkd.2017.10.026","volume":"71","author":"K Umanath","year":"2018","unstructured":"Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018;71(6):884\u201395.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1050_CR4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"1050_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12933-015-0204-5","volume":"14","author":"L Cea Soriano","year":"2015","unstructured":"Cea Soriano L, Johansson S, Stefansson B, Rodriguez LA. Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors. Cardiovasc Diabetol. 2015;14:38.","journal-title":"Cardiovasc Diabetol"},{"key":"1050_CR6","volume-title":"IDF diabetes atlas","author":"International Diabetes Federation","year":"2019","unstructured":"International Diabetes Federation. IDF diabetes atlas. 9th ed. Brussels, Belgium: International Diabetes Federation; 2019.","edition":"9"},{"key":"1050_CR7","unstructured":"Centers for Disease Control and Prevention. National diabetes statistics report, 2020. Atlanta: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2020."},{"issue":"12","key":"1050_CR8","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"1050_CR9","doi-asserted-by":"publisher","first-page":"e0168491","DOI":"10.1371\/journal.pone.0168491","volume":"11","author":"E Zimbudzi","year":"2016","unstructured":"Zimbudzi E, Lo C, Ranasinha S, Gallagher M, Fulcher G, Kerr PG, et al. Predictors of health-related quality of life in patients with co-morbid diabetes and chronic kidney disease. PLoS ONE. 2016;11(12):e0168491.","journal-title":"PLoS ONE"},{"key":"1050_CR10","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Kidney disease statistics for the United States 2020. https:\/\/www.niddk.nih.gov\/health-information\/health-statistics\/kidney-disease. Accessed Jan 2021."},{"key":"1050_CR11","unstructured":"United States Renal Data System. 2017 USRDS annual data report. Epidemiology of kidney disease in the United States. Bethesda: US Department of Health and Human Services, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2016. https:\/\/www.usrds.org\/adr.aspx. Accessed Jan 2021."},{"issue":"43","key":"1050_CR12","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.15585\/mmwr.mm6643a2","volume":"66","author":"NR Burrows","year":"2017","unstructured":"Burrows NR, Hora I, Geiss LS, Gregg EW, Albright A. Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes\u2014United States and Puerto Rico, 2000\u20132014. MMWR Morb Mortal Wkly Rep. 2017;66(43):1165\u201370.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"1050_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/jama.2015.0602","volume":"313","author":"AS Levey","year":"2015","unstructured":"Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015;313(8):837\u201346.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"1050_CR14","first-page":"S1","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2020;43(Suppl 1):S1\u2013204.","journal-title":"Diabetes Care"},{"key":"1050_CR15","doi-asserted-by":"crossref","unstructured":"Qaseem A, Hopkins RH Jr, Sweet DE, Starkey M, Shekelle P, Clinical Guidelines Committee of the American College of Physicians. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;159(12):835\u201347.","DOI":"10.7326\/0003-4819-159-12-201312170-00726"},{"issue":"12","key":"1050_CR16","first-page":"776","volume":"96","author":"DY Gaitonde","year":"2017","unstructured":"Gaitonde DY, Cook DL, Rivera IM. Chronic kidney disease: detection and evaluation. Am Fam Physician. 2017;96(12):776\u201383.","journal-title":"Am Fam Physician"},{"key":"1050_CR17","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4S):S1\u2013S115.","DOI":"10.1016\/j.kint.2020.06.019"},{"issue":"8","key":"1050_CR18","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1681\/ASN.2010010063","volume":"21","author":"HJ Lambers Heerspink","year":"2010","unstructured":"Lambers Heerspink HJ, Gansevoort RT, et al. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol. 2010;21(8):1355\u201360.","journal-title":"J Am Soc Nephrol"},{"issue":"15","key":"1050_CR19","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577\u201389.","journal-title":"N Engl J Med"},{"issue":"2","key":"1050_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","volume":"28","author":"Y Ohkubo","year":"1995","unstructured":"Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103\u201317.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"1050_CR21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/1753-0407.12624","volume":"10","author":"Z Bloomgarden","year":"2018","unstructured":"Bloomgarden Z, Handelsman Y. How does CKD affect HbA1c? J Diabetes. 2018;10(4):270.","journal-title":"J Diabetes"},{"issue":"2","key":"1050_CR22","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s11606-013-2595-x","volume":"29","author":"MS Radin","year":"2014","unstructured":"Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med. 2014;29(2):388\u201394.","journal-title":"J Gen Intern Med"},{"issue":"9889","key":"1050_CR23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339\u201352.","journal-title":"Lancet"},{"issue":"6","key":"1050_CR24","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334\u201357.","journal-title":"Hypertension"},{"issue":"12","key":"1050_CR25","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"1050_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2014.18574","volume":"313","author":"CA Emdin","year":"2015","unstructured":"Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603\u201315.","journal-title":"JAMA"},{"issue":"12","key":"1050_CR27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851\u201360.","journal-title":"N Engl J Med"},{"issue":"8","key":"1050_CR28","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2215\/CJN.00060119","volume":"14","author":"SL Tummalapalli","year":"2019","unstructured":"Tummalapalli SL, Powe NR, Keyhani S. Trends in quality of care for patients with CKD in the United States. Clin J Am Soc Nephrol. 2019;14(8):1142\u201350.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1050_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12882-015-0154-x","volume":"16","author":"L Samal","year":"2015","unstructured":"Samal L, Wright A, Waikar SS, Linder JA. Nephrology co-management versus primary care solo management for early chronic kidney disease: a retrospective cross-sectional analysis. BMC Nephrol. 2015;16:162.","journal-title":"BMC Nephrol"},{"issue":"1","key":"1050_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11606-015-3452-x","volume":"31","author":"AC Ricardo","year":"2016","unstructured":"Ricardo AC, Roy JA, Tao K, et al. Influence of nephrologist care on management and outcomes in adults with chronic kidney disease. J Gen Intern Med. 2016;31(1):22\u20139.","journal-title":"J Gen Intern Med"},{"key":"1050_CR31","doi-asserted-by":"crossref","unstructured":"Vassalotti JA, Centor R, Turner BJ, et al. Practical approach to detection and management of chronic kidney disease for the primary care clinician. Am J Med. 2016;129(2):153\u2013162.e7.","DOI":"10.1016\/j.amjmed.2015.08.025"},{"issue":"5","key":"1050_CR32","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","volume":"21","author":"T Toyama","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237\u201350.","journal-title":"Diabetes Obes Metab"},{"issue":"17","key":"1050_CR33","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022\u201331.","journal-title":"Circulation"},{"issue":"24","key":"1050_CR34","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"1050_CR35","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"10184","key":"1050_CR36","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","volume":"393","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10184):1937\u201347.","journal-title":"Lancet"},{"issue":"5","key":"1050_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000503713","volume":"50","author":"GL Bakris","year":"2019","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Design and baseline characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial. Am J Nephrol. 2019;50(5):333\u201344.","journal-title":"Am J Nephrol"},{"issue":"5","key":"1050_CR38","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000503712","volume":"50","author":"LM Ruilope","year":"2019","unstructured":"Ruilope LM, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol. 2019;50(5):345\u201356.","journal-title":"Am J Nephrol"},{"issue":"3","key":"1050_CR39","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1681\/ASN.2009060593","volume":"21","author":"JF Mann","year":"2010","unstructured":"Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21(3):527\u201335.","journal-title":"J Am Soc Nephrol"},{"issue":"23","key":"1050_CR40","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"23","key":"1050_CR41","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204\u201313.","journal-title":"N Engl J Med"},{"issue":"12","key":"1050_CR42","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","volume":"54","author":"E Imai","year":"2011","unstructured":"Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54(12):2978\u201386.","journal-title":"Diabetologia"},{"issue":"2","key":"1050_CR43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","volume":"25","author":"TA Mavrakanas","year":"2014","unstructured":"Mavrakanas TA, Gariani K, Martin PY. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Eur J Intern Med. 2014;25(2):173\u20136.","journal-title":"Eur J Intern Med"},{"issue":"8","key":"1050_CR44","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","volume":"20","author":"M Trevisan","year":"2018","unstructured":"Trevisan M, de Deco P, Xu H, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018;20(8):1217\u201326.","journal-title":"Eur J Heart Fail"},{"key":"1050_CR45","doi-asserted-by":"crossref","unstructured":"Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev. 2014(6):CD007333.","DOI":"10.1002\/14651858.CD007333.pub2"},{"issue":"7","key":"1050_CR46","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin andcardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"1050_CR47","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"1050_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334.","journal-title":"N Engl J Med"},{"issue":"4","key":"1050_CR49","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"1","key":"1050_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","volume":"9","author":"G Grunberger","year":"2018","unstructured":"Grunberger G, Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and Type 2 diabetes mellitus: The VERTIS renal randomized Study. Diabetes Ther. 2018;9(1):49\u201366.","journal-title":"Diabetes Ther"},{"issue":"9","key":"1050_CR51","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839\u201348.","journal-title":"N Engl J Med"},{"issue":"4","key":"1050_CR52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K,et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"1050_CR53","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"9","key":"1050_CR54","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"10193","key":"1050_CR55","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131\u20138.","journal-title":"Lancet"},{"issue":"10193","key":"1050_CR56","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"8","key":"1050_CR57","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1050_CR58","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2337\/dc19-1065","volume":"43","author":"MA Bethel","year":"2020","unstructured":"Bethel MA, Mentz RJ, Merrill P, et al. Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: Insights from the EXSCEL trial. Diabetes Care. 2020;43(2):446\u201352.","journal-title":"Diabetes Care"},{"issue":"11","key":"1050_CR59","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","volume":"6","author":"MHA Muskiet","year":"2018","unstructured":"Muskiet MHA, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):859\u201369.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"1050_CR60","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"key":"1050_CR61","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1\u2013150."}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01050-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-021-01050-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01050-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T07:06:15Z","timestamp":1675235175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-021-01050-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1050"],"URL":"https:\/\/doi.org\/10.1007\/s13300-021-01050-w","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"1 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}